By: Medical University of South Carolina From: scitechdaily.com Scientists have uncovered a powerful new antibody that disrupts a key protein helping triple-negative breast cancer survive and evade immunity. Triple-negative breast cancer (TNBC) is considered one of the most aggressive and difficult forms of breast cancer to treat. It grows rapidly, tends to spread at an early stage, and does not …
UCSF Study Finds a Better Way to Screen for Breast Cancer
By Elizabeth Fernandez From: ucsf.edu A pioneering study has found that an individualized approach to breast cancer screening that assesses patients’ risk, rather than automatically giving annual mammograms, can lower the chance of more advanced cancers, while still safely matching people to the amount of screening they need. The results — which come from 46,000 U.S. women enrolled in the …
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
By: Alexandra Gerlach From: pharmacytimes.com Key Takeaways ADCs target specific tumor antigens, enhancing therapeutic windows and efficacy, with HER2 and TROP-2 as key targets in breast cancer. HER2-targeting ADCs, T-DM1 and T-DXd, have shown significant benefits in early and metastatic breast cancer, improving survival and response rates. TROP-2-targeting ADCs, SG and Dato-DXd, are approved for metastatic breast cancer, showing efficacy …
Real-World Outcomes Favor Standard Care in HER2-Positive Metastatic Breast Cancer
By: Gregory Laub From: medpagetoday.com After the results of CLEOPATRA, taxane chemotherapy with dual anti-HER2-blocker therapy Herceptin [trastuzumab]/Perjeta [pertuzumab] became the standard of care for HER2-positive metastatic breast cancer. With this study, we were looking to see how many patients in the real world received that regimen as a first-line standard-of-care therapy, which we defined as “1LSOC” compared to an …
DETECT V: HER2+, HR+ Metastatic Breast Cancer can be Safely Treated Without Chemotherapy
By: Vicki Moore, PhD From: cancertherapyadvisor.com It may be possible to safely omit chemotherapy for patients with HER2-positive, hormone receptor (HR)-positive metastatic breast cancer, according to an updated analysis of the DETECT V study. Wolfgang Janni, MD, PhD, of the University Hospital Ulm in Ulm, Germany presented the findings at the San Antonio Breast Cancer Symposium 2025. The randomized, multicenter, …
What to Know About Metastatic Breast Cancer in Your 50s
From: healthline.com Although the average age of diagnosis for breast cancer in the United States is 62 yearsTrusted Source, the condition can also affect people in their 50s or at a younger age. Metastatic breast cancer (MBC) occurs when breast cancer spreads from your breast to other parts of your body. There’s currently no cure for MBC, but treatment may …
Novel endocrine therapy reduces the risk of breast cancer recurrence
By Denise Heady, MA From: uclahealth.org In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1-3) hormone receptor (HR)-positive, HER2-negative breast cancer, significantly lowered the risk of the disease returning when compared with standard hormone therapies long considered the …
How Pharmacists Help Drive Precision Oncology in Metastatic Breast Cancer
By: Danielle Valletti, Assistant Editor, Siddhartha Yadav, M.B.B.S., M.D. From: .pharmacytimes.com Pharmacists play a vital role in precision oncology, enhancing treatment decisions for metastatic breast cancer through genetic testing and targeted therapies. At the 2025 San Antonio Breast Cancer Symposium (SABCS), Siddhartha Yadav, MBBS, MD, discussed the critical and expanding role of pharmacists in precision oncology and biomarker-driven treatment decision-making …
The Latest on Emerging Therapies for Metastatic HR+/HER2- Breast Cancer
By: Shalmali Pal From: medpagetoday.com “Medical Journeys” is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient resource. “Medical Journeys” chart a path each step of the way for physicians and …
Integrative Therapy and Nurse Navigation Reduce Treatment Side Effects for 75% of Black Breast Cancer Patients; 85% Report Lower Distress
Leading breast cancer nonprofits Unite for HER and TOUCH, The Black Breast Cancer Alliance (TOUCHBBCA) presented new and critical research addressing health disparities, entitled “A New Comprehensive IntegrativeCare and Navigation Model for Enhancing Outcomes for Black Breast Cancer Patients: Evidence from the Care for HER Program” at the 2025 San Antonio Breast Cancer Symposium. The Care for HER Program, presented …